['ulcerative colitis']
['cobitolimod', 'placebo']

        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Established diagnosis of Ulcerative Colitis (UC)

          -  Moderately to severely active left sided UC assessed by central reading

          -  Current oral 5-Aminosalicylic Acid (5-ASA)/ Sulphasalazine (SP) use or a history of
             oral 5-ASA/SP use

          -  Current Glucocorticosteroids (GCS) use or history of GCS dependency, refractory, or
             intolerance

          -  Demonstrated an inadequate response, loss of response, or intolerance to at least one
             of the following agents:

               -  Immunomodulators

               -  Tumor Necrosis Factor alpha (TNF-α) inhibitors and/or anti-integrins

        Exclusion Criteria:

          -  Suspicion of differential diagnosis

          -  Acute fulminant UC and/or signs of systemic toxicity

          -  UC limited to the rectum (disease which extend <15 cm above the anal verge)

          -  History of malignancy

          -  History or presence of any clinically significant disorder

          -  Concomitant treatment with cyclosporine, methotrexate, tacrolimus, TNF-α inhibitors,
             anti-integrins or similar immunosuppressants and immunomodulators

          -  Treatment with rectal GCS, 5-ASA/SP or tacrolimus

          -  Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Serious active infection

          -  Gastrointestinal infections

          -  Currently receiving parenteral nutrition or blood transfusions

          -  Females who are lactating or have a positive serum pregnancy test

          -  Women of childbearing potential not using reliable contraceptive methods

          -  Concurrent participation in another clinical study

          -  Previous exposure to cobitolimod
      